Related Experiment Video
Updated: May 3, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications
Jennifer E Kim1, Mira Patel2, Jacob Ruzevick3
1Department of Neurosurgery, The Johns Hopkins University School of Medicine, 600 N. Wolfe St., Phipps Building Rm 123, Baltimore, MD 21287, USA. jkim256@jhmi.edu.
Abstract:
Signal transducer and activator of transcription 3 (STAT3) is a potent regulator of gliomagenesis through its induction of angiogenesis, host immunosuppression, and tumor invasion. Gain of function mutations result in constitutive activation of STAT3 in glioma cells, making STAT3 an attractive target for inhibition in cancer therapy. Nevertheless, some studies show that STAT3 also participates in terminal differentiation and apoptosis of various cell lines and in glioma with phosphatase and tensin homolog (PTEN)-deficient genetic backgrounds. In light of these findings, the utility of STAT3 as a prognostic indicator and as a target of drug therapies will be contingent on a more nuanced understanding of its pro- and anti-tumorigenic effects.
Insights
Signal transducer and activator of transcription 3 (STAT3) promotes glioma development but may also induce cell death. Further research is needed to understand STAT3
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Signal transducer and activator of transcription 3 (STAT3) is a key regulator in gliomagenesis.
- STAT3 activation drives angiogenesis, immunosuppression, and tumor invasion in gliomas.
- Constitutive STAT3 activation due to gain-of-function mutations makes it a therapeutic target.
Purpose of the Study:
- To explore the dual role of STAT3 in glioma.
- To investigate the pro- and anti-tumorigenic effects of STAT3.
- To determine the utility of STAT3 as a prognostic indicator and therapeutic target.
Main Methods:
- Literature review of STAT3's role in gliomagenesis.
- Analysis of studies on STAT3 in various cell lines and PTEN-deficient gliomas.
- Synthesis of findings on STAT3's pro- and anti-tumorigenic activities.
Main Results:
- STAT3 promotes glioma development through angiogenesis, immunosuppression, and invasion.
- STAT3 also exhibits anti-tumorigenic roles, including terminal differentiation and apoptosis.
- These opposing roles are observed in various cell lines and PTEN-deficient gliomas.
Conclusions:
- STAT3 has a complex role in glioma, acting as both a promoter and inhibitor of tumor progression.
- Understanding the nuanced effects of STAT3 is crucial for its application as a prognostic marker.
- Further research is required to fully elucidate STAT3's dual function for effective cancer therapy development.
